Oncolytic viral therapy engenders a clinical response in a recurrent ovarian cancer patient
Platinum-resistant ovarian cancer frequently develops in response to multiple lines of chemotherapy, whereupon the disease becomes relatively intractable and clinical recourse is limited. We document a 58-year-old, advanced-stage, platinum-resistant ovarian cancer patient who previously failed numerous cytotoxic and targeted therapy regimens. She was referred to our gynecologic oncology service with a California (CA)-125 of 3194 U/mL and underwent a modified vaccinia virus coinciding with an Institutional Review Board-approved clinical trial. Following the oncolytic therapy and cycle 8 chemotherapy, the patient’s CA-12...
Source: Anti-Cancer Drugs - April 20, 2022 Category: Cancer & Oncology Tags: Case Reports Source Type: research

Pyrotinib for HER2-amplified non-small cell lung cancer patient after progression to Afatinib: a case report
In this report, a nonsmoker, Chinese, old, male patient was diagnosed with cT2bN3M0 nonsmall cell lung cancer with genetic testing revealing HER2 amplification. Though the patient received successful microwave ablation, the results of reexamination after two cycles of afatinib monotherapy showed disease progression. Then the treatment regimen was switched to pan-HER inhibitor pyrotinib 400 mg daily, with which the patient remained with stable disease for 9 months. After computed tomography showed tumor enlargement in October 2021, anlotinib was added to the present treatment. This case suggests that pyrotinib may provide...
Source: Anti-Cancer Drugs - April 20, 2022 Category: Cancer & Oncology Tags: Case Reports Source Type: research

Inhibiting nonhomologous end-joining repair would promote the antitumor activity of gemcitabine in nonsmall cell lung cancer cell lines
Nonsmall cell lung cancer (NSCLC) is a major type of lung cancer. In current study, we aim to evaluate whether the combination of Ku70/80 heterodimer protein inhibitor STL127705 and gemcitabine would be more favorable approach for the treatment of NSCLC compared with monotreatment with gemcitabine. Clongenic survival assay was used to determine the survival and sensitivity to irradiation. H1299 was stained with fluorescein isothiocyanate-Annexin V, and cell apoptosis was measured by flow cytometry. H1299 cells were transfected with nonhomologous end-joining (NHEJ) repair reporter, and stable cell line was selected by purom...
Source: Anti-Cancer Drugs - April 20, 2022 Category: Cancer & Oncology Tags: Original Studies Source Type: research

TRIM72 exerts antitumor effects in breast cancer and modulates lactate production and MCT4 promoter activity by interacting with PPP3CA
A hypoxic tumor microenvironment (TME) promotes cancer progression, yet its value as a therapeutic target remains underexploited. Tripartite motif-containing 72 (TRIM72) may protect cells against various stresses including hypoxia. Recently, low TRIM72 expression has been implicated in cancer progression. However, the biological role and molecular mechanism of TRIM72 in breast cancer (BC) remain unclear. Herein, we analyzed the TRIM72 expression in BC tissue and cell lines by western blot (WB) and quantitative reverse transcription-PCR. We established the overexpression of TRIM72 using plasmids and lentiviral-mediated upre...
Source: Anti-Cancer Drugs - April 20, 2022 Category: Cancer & Oncology Tags: Original Studies Source Type: research

MicroRNA hsa-miR-657 promotes retinoblastoma malignancy by inhibiting peroxisome proliferator-activated receptor alpha expression
This study provides novel insights into the miR-657- and PPARA-mediated mechanisms underlying retinoblastoma progression and suggests that the interaction between miR-657 and PPARA may serve as an effective target for therapeutic intervention. (Source: Anti-Cancer Drugs)
Source: Anti-Cancer Drugs - April 20, 2022 Category: Cancer & Oncology Tags: Original Studies Source Type: research

Expression and clinical significance of CXCL17 and GPR35 in endometrial carcinoma
Endometrial carcinoma is one of the most common gynecologic malignancies. CXCL17-CXCR8 (GPR35) axis is reported to play an indispensability role in tumors. Our purpose is to screen possible prognostic and immune-related factors in endometrial carcinoma by detecting the mRNA and protein expression of CXCL17 and CXCR8. We use the qRT-PCR method to test the mRNA expression of CXCL17 and CXCR8 in 35 pairs of endometrial carcinoma and adjacent tissue. The protein expression of CXCL17 and CXCR8 in 30 cases of normal proliferative endometrium, 30 cases of endometrial atypical hyperplasia and 50 cases of endometrial carcinoma was ...
Source: Anti-Cancer Drugs - April 20, 2022 Category: Cancer & Oncology Tags: Original Studies Source Type: research

Sarcopenia and the rate of change of the neutrophil/lymphocyte ratio as predictors of pembrolizumab efficacy in advanced urothelial carcinoma
The objective was to evaluate the usefulness of sarcopenia and the neutrophil/lymphocyte ratio (NLR) as therapeutic efficacy predictors in patients who received pembrolizumab after platinum-based chemotherapy for advanced urothelial carcinoma (aUC). Forty-four patients with aUC were enrolled. Patients’ background characteristics and clinical factors, the skeletal muscle index, and the psoas muscle index were evaluated. The NLR before and during treatment was calculated, and the rate of change of NLR was calculated. The median age was 70 years; the follow-up period was 13.2 months. The response rate was 54%. The nonrespon...
Source: Anti-Cancer Drugs - April 20, 2022 Category: Cancer & Oncology Tags: Clinical Report Source Type: research

Dexmedetomidine disrupts esophagus cancer tumorigenesis by modulating circ_0003340/miR-198/HMGA2 axis
This study aimed to investigate the role of DEX in esophagus cancer and its underlying mechanism. Cell Counting Kit-8 assay and 5-ethynyl-2′-deoxyuridine assays were conducted to evaluate cell proliferation. Flow cytometry analysis and transwell assay were performed for cell apoptosis and invasion. The protein levels of cleaved caspase-3, matrix metallopeptidase 9, and high mobility group AT-hook 2 (HMGA2) were assessed by western blot assay. The expression levels of circ_0003340 and microRNA-198 (miR-198) were determined by quantitative real-time PCR. Dual-luciferase reporter assay was performed to verify the interactio...
Source: Anti-Cancer Drugs - April 20, 2022 Category: Cancer & Oncology Tags: Pre-Clinical Reports Source Type: research

CircFOXK2 enhances tumorigenesis and immune evasion in non–small cell lung cancer by miR-485-5p/PD-L1 axis
Conclusion CircFOXK2 sponged miR-485-5p to stimulate PD-L1 and expedited NSCLC development. (Source: Anti-Cancer Drugs)
Source: Anti-Cancer Drugs - April 20, 2022 Category: Cancer & Oncology Tags: Pre-Clinical Reports Source Type: research

The marine factor 3,5-dihydroxy-4-methoxybenzyl alcohol suppresses growth, migration and invasion and stimulates death of metastatic human prostate cancer cells: targeting diverse signaling processes
This study may provide a new strategy for prostate cancer therapy with DHMBA. (Source: Anti-Cancer Drugs)
Source: Anti-Cancer Drugs - April 20, 2022 Category: Cancer & Oncology Tags: Pre-Clinical Reports Source Type: research

Mechanisms of GZ17-6.02 resistance
Conclusions Our findings demonstrate that GZ17-6.02 has the potential to be developed as a colon cancer therapeutic and that resistance to the drug can be partially reversed by HDAC inhibitors. (Source: Anti-Cancer Drugs)
Source: Anti-Cancer Drugs - April 20, 2022 Category: Cancer & Oncology Tags: Pre-Clinical Reports Source Type: research

MicroRNA-301b and its target gene synaptosome-associated protein 91 as important modulators in esophageal cancer: functional experiments: Retraction
No abstract available (Source: Anti-Cancer Drugs)
Source: Anti-Cancer Drugs - March 11, 2022 Category: Cancer & Oncology Tags: Retractions Source Type: research

Propranolol suppresses infantile hemangioma cell proliferation and promotes apoptosis by upregulating miR-125b expression: Retraction
No abstract available (Source: Anti-Cancer Drugs)
Source: Anti-Cancer Drugs - March 11, 2022 Category: Cancer & Oncology Tags: Retractions Source Type: research

Aumolertinib-based comprehensive treatment for an uncommon site of EGFR exon 20 insertion mutations with multiple metastases non-small cell lung cancer: a case report
This study aimed to share a case of applying aumolertinib as the core combined with other treatments for a patient with multiple metastases in NSCLC with an uncommon site of EGFR exon 20 insertion mutations. The comprehensive treatment benefited the patient in terms of 10 months of progression-free survival and a significant improvement in quality of life. We discussed whether we could further explore the potential of aumolertinib in treating EGFR exon 20 insertion mutations through this case report. (Source: Anti-Cancer Drugs)
Source: Anti-Cancer Drugs - March 11, 2022 Category: Cancer & Oncology Tags: Case Reports Source Type: research

Dramatic response to crizotinib in a breast cancer patient with ALK gene rearrangement
Rearrangements of the anaplastic lymphoma kinase (ALK) gene are present in 3–5% of non–small-cell lung cancer (NSCLC), while it was 0.2% in NSCLC tumors. Due to its low frequency, it is extremely challenging to conduct randomized clinical trials of ALK-targeted therapies in NSCLC tumors. In the present case, we describe the first reported case of triple-negative breast cancer (TNBC) harboring the ALK fusion mutation that responded to ALK-targeted therapy after progression with two lines of chemotherapy. Searching for ALK gene rearrangement or other fusion, especially in patients with chemotherapy-resistant TNBC, opens ...
Source: Anti-Cancer Drugs - March 11, 2022 Category: Cancer & Oncology Tags: Case Reports Source Type: research